ATGAM

Indicated For

Aplastic anemia (moderate to severe), Renal transplant rejection, Graft-versus-host disease, Myelodysplastic syndrome

About This Medication

# Pfizer RxPathways Patient Guide: How to Get ATGAM (lymphocyte immune globulin, anti-thymocyte globulin (equine)) at Low or No Cost ATGAM is a prescription medicine used to manage acute rejection in renal transplant patients and treat moderate to severe aplastic anemia in those not suitable for bone marrow transplantation. Pfizer RxPathways offers this medication for free to eligible patients who meet financial need criteria, regardless of insurance status.[7][6] ## About ATGAM **ATGAM (lymphocyte immune globulin, anti-thymocyte globulin [equine])** is an immunosuppressant administered intravenously in a hospital or clinic setting. It works by targeting and depleting certain immune cells (T-lymphocytes) to prevent or treat organ rejection after kidney transplants and to manage aplastic anemia, a condition where the bone marrow fails to produce enough blood cells.[7] Common uses include: - Reversing acute kidney transplant rejection when used with standard therapies. - Treating aplastic anemia in patients unfit for bone marrow transplants. **Important safety notes:** ATGAM carries risks like anaphylaxis, cytokine release syndrome, infections, and serum sickness. It must be given under close medical supervision with monitoring for allergic reactions during and after infusion. Always discuss risks with your doctor.[7] This guide focuses on accessing ATGAM through Pfizer RxPathways, the patient assistance program (PAP) from Pharmacia & Upjohn Company LLC, a Pfizer company.[1] ## Who Qualifies for Pfizer RxPathways? Pfizer RxPathways provides free medicines to US patients facing financial hardship. Eligibility typically includes: - US citizens, residents, or legal aliens. - Household income at or below **400-500% of the Federal Poverty Level (FPL)**, depending on the medicine and program tier (exact thresholds vary; use the online tool for your situation). - Prescription for an eligible Pfizer medicine like ATGAM. - Financial need, demonstrated by income or other proofs.[1][2][10] The program serves both **insured and uninsured patients**. Medicare patients may qualify if they meet income guidelines, as the program bridges gaps in coverage.[2] ## Income Eligibility Breakdown Specific income thresholds for ATGAM are not publicly listed and depend on household size, but Pfizer follows federal guidelines. Use the Program Finder on PfizerRxPathways.com for personalized eligibility. Here's a general example based on 2026 FPL (approximate; confirm via program): | Household Size | 400% FPL (Annual Income) | 500% FPL (Annual Income) | |---------------|---------------------------|---------------------------| | 1 | $60,240 | $75,300 | | 2 | $81,760 | $102,200 | | 3 | $103,280 | $129,100 | | 4 | $124,800 | $156,000 | | +1 person | +$21,520 | +$26,900 | *Note: These are estimates. Households above these may still qualify via other Pfizer programs like co-pay assistance. No assets test is typically required, but proof like tax returns may be needed.[3][9] ## Insurance Requirements Pfizer RxPathways accepts patients with **any insurance**, including Medicare, Medicaid (with limits), or commercial plans. The program provides free medicine if your out-of-pocket costs are unaffordable due to high copays, deductibles, or no coverage. Medicare Part D patients often qualify if income-eligible, as PAPs fill coverage gaps. However, if Medicaid covers the drug fully, you may not qualify. Always check via the online tool.[2][10] ## Step-by-Step Application Process Applying is straightforward with **multiple methods**: online, phone, or paper.[1] 1. **Check Eligibility Online (Fastest):** Visit www.PfizerRxPathways.com. Use the **Program Finder**: - Enter "ATGAM". - Answer questions on income, household size, insurance, and prescription. - Get instant matches and start application.[1][9] 2. **Online via Pfizer PAP Connect (Recommended for ATGAM if eligible):** Go to www.PfizerPAPConnect.com. - Register as a new patient (email and details) or log in if enrolled. - Complete form, upload documents (income proof like pay stubs, tax returns). - Track status and request refills online.[2] 3. **Phone Assistance:** Call **(800) 505-4426** (Pfizer RxPathways) or 1-844-989-PATH (7284). Counselors guide you, mail forms, or process verbally.[1][3] 4. **Healthcare Provider Help:** Your doctor or office staff can apply via PAP Connect (they register with NPI first).[2] 5. **Submit Documents:** May include proof of income, residency, prescription, and insurance details. Upload online or mail.[3] 6. **Sign and Wait:** e-Sign digitally or mail signed forms.[1] ## Timeline and Delivery - **Processing:** 2-3 weeks for approval notification.[1][3] - **Delivery:** Free medicine shipped to your doctor's office or pharmacy for pickup/dispensing. Hospital-administered drugs like ATGAM go directly to the facility.[1] - **Supply Duration:** Typically 1-12 months per approval; refills via PAP Connect or phone.[2] ## Alternatives if Denied or Ineligible - **Other Pfizer Programs:** Co-pay cards or insurance navigation via Pfizer RxPathways.[10] - **NeedyMeds or RxAssist:** Search for ATGAM alternatives.[General knowledge] - **State Programs:** Check Medicaid or transplant funds. - **Manufacturer Hub:** ATGAM-specific support at atgam.pfizerpro.com.[7] - **Generic/Biosimilars:** No direct biosimilars listed; discuss rabbit ATG (Thymoglobulin) with your doctor.[General knowledge] ## Reauthorization and Refills Annual re-enrollment required. Use PAP Connect for easy refills and status checks. Submit updated income proof yearly.[2] ## Disclaimer This guide is for informational purposes only and based on publicly available data as of 2026. Eligibility, processes, and availability can change. Contact Pfizer RxPathways directly at (800) 505-4426 or www.PfizerRxPathways.com for latest details. Consult your healthcare provider before starting ATGAM. Pfizer does not guarantee approval. Not affiliated with government programs.

Program information last verified: March 30, 2026